Cubist Pharmaceuticals Inc - CBST - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 26, 2013

Cubist Pharmaceuticals Inc - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
CBST	Nasdaq	2834	http://www.cubist.com/	55.49 -0.54
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Cubist Pharmaceuticals Inc Analysts: Williams-Sonoma Has International Growth Potential and 3 More Research Notes to Read - May 24th, 2013 11:46 am Priority FDA Review for Celgene's Abraxane - May 24th, 2013 8:30 am Cubist downgraded at Janney Capital - May 24th, 2013 5:22 am NPS Pharma Prices Offering - May 23rd, 2013 4:40 pm Is There a Future for Small Pharma? - May 23rd, 2013 2:31 pm Cubist to Present at Jefferies 2013 Global Healthcare Conference - May 23rd, 2013 2:30 pm Do These Tuesday Upgrades Present a Buying Opportunity? - May 23rd, 2013 10:00 am Cubist Pharmaceuticals Inc. (CBST): Today's Featured Health Care Winner - May 22nd, 2013 3:00 pm Cubist, Optimer, Trius: Antibiotic Deal Making On Tap - May 22nd, 2013 5:00 am Cubist Rises On Unusually High Volume (CBST) - May 21st, 2013 10:25 am Ahead of the Bell: Analyst upgrades Cubist Pharma - May 21st, 2013 7:12 am Ahead of the Bell: Analyst upgrades Cubist Pharma - May 21st, 2013 7:12 am Analysts' Actions: CBST CNW COH TMHC VFC - May 21st, 2013 6:24 am Cubist price target raised to $63 from $53 at RBC Capital - May 21st, 2013 5:17 am 2013 FDA Drug Approval Calendar - May 21st, 2013 5:00 am Cubist Pharma upgraded by Cantor Fitzgerald - May 20th, 2013 9:52 pm U.S. court ruling favors Cubist in patent case versus Hospira - May 20th, 2013 4:57 pm U.S. court ruling favors Cubist in patent case vs Hospira - May 20th, 2013 4:49 pm Cubist Pharmaceuticals shares leap late after ruling on patent cases - May 20th, 2013 3:16 pm Cubist move higher attributed to patent construction in suit against Hospira - May 20th, 2013 1:56 pm View All Current Headlines >>